87 Kodiak Sciences Inc. Consolidated Statements of Stockholders’ Equity (in thousands, except share and per share amounts) Common Stock Additional Paid-In Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balances at December 31, 2021........................ 51,826,257 $ 5 $ 1,221,532 $ — $ (558,217) $ 663,320 Issuance of common stock upon exercise of stock options.......................... 126,999 — 1,770 — — 1,770 Issuance of common stock upon vesting of restricted stock units................................................ 103,032 — — — — — Issuance of common stock pursuant to employee stock purchase plan...................................... 27,863 — 174 — — 174 Issuance of common stock upon exercise of common stock warrants............................................ 249,699 — — — — — Stock-based compensation expense ............................................ — — 106,033 — — 106,033 Other comprehensive loss .......................... — — — (1,307) — (1,307) Net loss .............................................. — — — — (333,823) (333,823) Balances at December 31, 2022........................ 52,333,850 5 1,329,509 (1,307) (892,040) 436,167 Issuance of common stock upon exercise of stock options.......................... 7,528 — 60 — — 60 Issuance of common stock upon vesting of restricted stock units................................................ 116,403 — — — — — Issuance of common stock pursuant to employee stock purchase plan...................................... 50,821 — 182 — — 182 Stock-based compensation expense ............................................ — — 88,556 — — 88,556 Other comprehensive income....................... — — — 1,307 — 1,307 Net loss .............................................. — — — — (260,491) (260,491) Balances at December 31, 2023........................ 52,508,602 5 1,418,307 — (1,152,531) 265,781 Issuance of common stock upon exercise of stock options.......................... 82,790 — 394 — — 394 Issuance of common stock upon vesting of restricted stock units................................................ 86,559 — — — — — Issuance of common stock pursuant to employee stock purchase plan...................................... 48,965 — 107 — — 107 Stock-based compensation expense ............................................ — — 60,213 — — 60,213 Net loss .............................................. — — — — (176,207) (176,207) Balances at December 31, 2024........................ 52,726,916 $ 5 $ 1,479,021 $ — $ (1,328,738) $ 150,288 The accompanying notes are an integral part of these consolidated financial statements.